SENSE4CARE SL

Their core work

SENSE4CARE is a Barcelona-based SME that develops unobtrusive sensor-based systems for continuous monitoring and quantitative assessment of Parkinson's disease. Their technology focuses on capturing objective movement data to support clinical decision-making and optimize treatment. More recently, they have expanded into smart living environments that detect early health and social risks in vulnerable populations, applying their sensor and data analytics expertise beyond neurodegenerative disease.

What they specialise in

How they've shifted over time

SENSE4CARE began with a tight focus on Parkinson's disease, progressing from a feasibility study (PARK-IT, SME Phase 1, 2015) to a full development project (PARK-IT 2.0, SME Phase 2, 2017–2019). By 2019, they joined GATEKEEPER, a large-scale innovation action targeting broader health and social risk detection in smart home settings. This shows a clear trajectory from a single-disease monitoring tool toward a general-purpose health sensing platform applicable to wider populations.

SENSE4CARE is broadening from disease-specific monitoring toward general population health sensing in home environments, signaling readiness for projects in elderly care, chronic disease management, and preventive health.

How they like to work

SENSE4CARE led both of their early projects as coordinator (PARK-IT and PARK-IT 2.0), demonstrating confidence in driving R&D agendas. They then joined GATEKEEPER as a participant in a large consortium, showing willingness to contribute specialist expertise within bigger teams. With 52 unique partners across 16 countries, they have built a surprisingly broad network for a company of just three projects, largely through the large GATEKEEPER consortium.

Despite only three projects, SENSE4CARE has collaborated with 52 unique partners across 16 countries, primarily through the large GATEKEEPER consortium. Their network spans much of Europe, giving them wide reach for a small SME.

What sets them apart

SENSE4CARE combines deep domain expertise in movement disorder monitoring with practical experience in unobtrusive sensor deployment — a niche that very few SMEs occupy. Their successful SME Instrument Phase 1-to-Phase 2 progression (PARK-IT to PARK-IT 2.0) demonstrates both technical credibility and commercial viability validated by the EU. For consortium builders, they bring a proven sensor platform that can be adapted from neurological assessment to broader smart health applications.

Highlights from their portfolio

• PARK-IT 2.0
  Successful SME Instrument Phase 2 project (EUR 699K) — demonstrates the company cleared both Phase 1 feasibility and Phase 2 development gates for their Parkinson's monitoring technology.
• GATEKEEPER
  Large-scale innovation action on smart living homes, marking SENSE4CARE's expansion from disease-specific tools to population-level health monitoring in home environments.